NASDAQ:AVBP | Cash Flow Statement | ArriVent BioPharma, Inc.

Complete source-backed cash-flow history.

Available history
2023-03-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$49.89M
2026-03-31-$43.32M-$41.89M$3.58M$54.87M
2025-12-31-$35.54M-$30.66M-$71.2M$34.73M
2025-09-30-$34.98M
2025-06-30-$31.4M
2025-03-31-$64.39M-$68.01M$36.82M$6.76M
2024-12-31-$20.63M-$16.15M$55,000.00
2024-09-30-$20.56M
2024-06-30-$21.87M
2024-03-31-$17.42M-$18.63M$185.63M
2023-12-31-$21.19M-$14.91M-$1.06M
2023-09-30-$14.4M
2023-06-30-$21.57M
2023-03-31-$12.17M-$16.88M$44.97M

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$166.31M-$160.59M-$71.23M$203.06M
2024-12-31-$80.49M-$70.21M-$192.47M$186.58M
2023-12-31-$69.33M-$55.84M$42.86M